JP2018515474A - 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 - Google Patents

抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 Download PDF

Info

Publication number
JP2018515474A
JP2018515474A JP2017556652A JP2017556652A JP2018515474A JP 2018515474 A JP2018515474 A JP 2018515474A JP 2017556652 A JP2017556652 A JP 2017556652A JP 2017556652 A JP2017556652 A JP 2017556652A JP 2018515474 A JP2018515474 A JP 2018515474A
Authority
JP
Japan
Prior art keywords
antibody
patient
ctla
antigen
binding portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017556652A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515474A5 (cg-RX-API-DMAC7.html
Inventor
アービン・ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56069213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2018515474(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2018515474A publication Critical patent/JP2018515474A/ja
Publication of JP2018515474A5 publication Critical patent/JP2018515474A5/ja
Priority to JP2021037372A priority Critical patent/JP2021105001A/ja
Priority to JP2024018859A priority patent/JP2024063028A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2017556652A 2015-04-28 2016-04-28 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 Pending JP2018515474A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021037372A JP2021105001A (ja) 2015-04-28 2021-03-09 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置
JP2024018859A JP2024063028A (ja) 2015-04-28 2024-02-09 抗ｐｄ－１抗体を使用するｐｄ－ｌ１陽性黒色腫の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562153954P 2015-04-28 2015-04-28
US62/153,954 2015-04-28
PCT/US2016/029878 WO2016176504A1 (en) 2015-04-28 2016-04-28 Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021037372A Division JP2021105001A (ja) 2015-04-28 2021-03-09 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置

Publications (2)

Publication Number Publication Date
JP2018515474A true JP2018515474A (ja) 2018-06-14
JP2018515474A5 JP2018515474A5 (cg-RX-API-DMAC7.html) 2019-06-13

Family

ID=56069213

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017556652A Pending JP2018515474A (ja) 2015-04-28 2016-04-28 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置
JP2021037372A Pending JP2021105001A (ja) 2015-04-28 2021-03-09 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置
JP2024018859A Pending JP2024063028A (ja) 2015-04-28 2024-02-09 抗ｐｄ－１抗体を使用するｐｄ－ｌ１陽性黒色腫の処置

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021037372A Pending JP2021105001A (ja) 2015-04-28 2021-03-09 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置
JP2024018859A Pending JP2024063028A (ja) 2015-04-28 2024-02-09 抗ｐｄ－１抗体を使用するｐｄ－ｌ１陽性黒色腫の処置

Country Status (6)

Country Link
US (3) US20160362489A1 (cg-RX-API-DMAC7.html)
EP (1) EP3288980B1 (cg-RX-API-DMAC7.html)
JP (3) JP2018515474A (cg-RX-API-DMAC7.html)
KR (2) KR20170140316A (cg-RX-API-DMAC7.html)
ES (1) ES2861352T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016176504A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11407830B2 (en) 2017-01-09 2022-08-09 Tesaro, Inc. Methods of treating cancer with anti-PD-1 antibodies

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
WO2013173223A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
KR20170138555A (ko) 2015-04-28 2017-12-15 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 항-ctla-4 항체를 사용한 pd-l1-음성 흑색종의 치료
HK1250033A1 (zh) 2015-07-13 2018-11-23 Cytomx Therapeutics Inc. 抗-pd-1抗体、可活化的抗-pd-1抗体、及其使用方法
UA124379C2 (uk) 2015-08-11 2021-09-08 Усі Байолоджікс Айрленд Лімітед Нові антитіла проти білка pd-1
AU2016317915B2 (en) 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
LT3377534T (lt) * 2015-11-18 2025-08-11 Bristol-Myers Squibb Company Plaučių vėžio gydymas, panaudojant anti-pd-1 antikūno ir anti ctla-4 antikūno derinį
EP3970719A1 (en) 2016-09-12 2022-03-23 Intra-Cellular Therapies, Inc. Pde1 inhibitor for use in a method of treatment or prophylaxis of inflammation and/or an inflammatory disease or disorder
EP3551225A1 (en) 2016-12-07 2019-10-16 Agenus Inc. Antibodies and methods of use thereof
CN110637031B (zh) * 2017-03-04 2024-04-16 湘潭腾华生物科技有限公司 程序性死亡蛋白1(pd-1)的重组抗体及其用途
EP3600426A4 (en) * 2017-03-31 2021-01-20 Merck Sharp & Dohme Corp. COMPOSITIONS AND METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTAGONIST OF PD-1 AND AN ANTI-CTLA4 ANTIBODY
US20210101980A1 (en) * 2017-03-31 2021-04-08 Bristol-Myers Squibb Company Methods of treating tumor
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
DK3631454T3 (da) 2017-05-30 2023-12-04 Bristol Myers Squibb Co Behandling af lag-3 positive tumorer
MX2019012076A (es) 2017-05-30 2019-12-09 Bristol Myers Squibb Co Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1).
EP3421607A1 (en) * 2017-06-29 2019-01-02 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Identification and elimination of damaged and/or senescent cells
EP3694884A1 (en) 2017-10-15 2020-08-19 Bristol-Myers Squibb Company Methods of treating tumor
US11685782B2 (en) 2017-10-23 2023-06-27 Children's Medical Center Corporation Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
WO2019084313A1 (en) * 2017-10-27 2019-05-02 Board Of Regents, The University Of Texas System USE OF SDHA AS PROGNOSTIC MARKER AND THERAPEUTIC TARGET FOR UREAL MELANOMA
CN111727060B (zh) * 2017-12-18 2023-04-11 德彪药业国际股份公司 治疗癌症的激动剂抗PD-1抗体与GnRH激动剂或GnRH拮抗剂的组合
MA51844A (fr) * 2018-02-13 2021-05-19 Merck Sharp & Dohme Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4
CA3090995A1 (en) * 2018-02-13 2019-08-22 Merck Sharp & Dohme Corp. Methods for treating cancer with anti-pd-1 antibodies
MX2020009552A (es) 2018-03-21 2020-10-05 Olatec Therapeutics Llc Composiciones para prevenir y/o tratar melanoma.
US20210347889A1 (en) * 2018-11-05 2021-11-11 Merck Sharp & Dohme Corp. Dosing regimen of anti-lag3 antibody and combination therapy with anti-pd-1 antibody for treating cancer
MX2021005394A (es) 2018-11-07 2021-07-06 Merck Sharp & Dohme Llc Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
WO2020118208A1 (en) * 2018-12-07 2020-06-11 Arizona Board Of Regents On Behalf Of The University Of Arizona A method of determining risk for skin cancer development and skin cancer therapeutic prevention by measuring pd-1/pd-l1 signaling pathway members
EP3908285A4 (en) 2019-01-07 2022-10-19 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
CN113244386A (zh) * 2020-02-13 2021-08-13 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗肿瘤中的用途
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173223A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
ES2282133T3 (es) 1999-08-24 2007-10-16 Medarex, Inc. Anticuerpos frente a la ctla-4 humano y sus usos.
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP2007423A2 (en) 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
WO2010027423A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
TWI605828B (zh) 2008-12-09 2017-11-21 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
ES2699965T3 (es) 2011-03-10 2019-02-13 Provectus Pharmatech Inc Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer
EP3403672A1 (en) 2011-04-20 2018-11-21 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
EP2734551B1 (en) 2011-07-24 2018-01-10 Cure Tech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
HUE060420T2 (hu) 2013-09-13 2023-02-28 Beigene Switzerland Gmbh Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk
RS64268B1 (sr) 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
CN106714839A (zh) 2014-05-15 2017-05-24 百时美施贵宝公司 使用抗pd‑1抗体和另一种抗癌剂的组合治疗肺癌
CA2955612C (en) * 2014-07-18 2022-05-17 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
HRP20210440T1 (hr) * 2014-10-29 2021-04-30 Five Prime Therapeutics, Inc. Kombinirana terapija za rak
US20180133313A1 (en) * 2014-12-16 2018-05-17 Bristol-Myers Squibb Company Use of immune checkpoint inhibitors in central nervous systems neoplasms
ES2813580T3 (es) 2015-04-17 2021-03-24 Bristol Myers Squibb Co Composiciones que comprenden una combinación de ipilimumab y nivolumab
HUE061253T2 (hu) * 2015-05-29 2023-06-28 Bristol Myers Squibb Co Antitestek OX40 ellen és azok felhasználásai
US10392442B2 (en) * 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
CN108602892A (zh) * 2016-01-27 2018-09-28 百时美施贵宝公司 使用抗-pd-1抗体和另一种抗癌剂的组合治疗肺癌
EP3691643A4 (en) * 2017-09-29 2021-06-16 Bristol-Myers Squibb Company COMPOSITIONS AND METHODS OF TREATMENT OF CANCER

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173223A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLINICAL CANCER RESEARCH, vol. VOL:19, NR:19, JPN5018002347, 1 October 2013 (2013-10-01), pages 5300 - 5309, ISSN: 0004381854 *
CLINICAL THERAPEUTICS, vol. VOL:37, NR:4, JPN5018002349, 1 April 2015 (2015-04-01), pages 764 - 782, ISSN: 0004381856 *
INTERNATIONAL IMMUNOLOGY, vol. VOL:27, NR:1, JPN5018002348, 16 October 2014 (2014-10-16), pages 39 - 46, ISSN: 0004381855 *
JOURNAL OF CELLULAR PHYSIOLOGY, vol. VOL:230, NR:11, JPN5018002351, 22 April 2015 (2015-04-22), pages 2626 - 2633, ISSN: 0004381857 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11407830B2 (en) 2017-01-09 2022-08-09 Tesaro, Inc. Methods of treating cancer with anti-PD-1 antibodies
US12415855B2 (en) 2017-01-09 2025-09-16 Tesaro, Inc. Methods of treating cancer with anti-PD-1 antibodies

Also Published As

Publication number Publication date
JP2021105001A (ja) 2021-07-26
EP3288980A1 (en) 2018-03-07
US20160362489A1 (en) 2016-12-15
JP2024063028A (ja) 2024-05-10
WO2016176504A1 (en) 2016-11-03
US20200010549A1 (en) 2020-01-09
ES2861352T3 (es) 2021-10-06
US20220281974A1 (en) 2022-09-08
KR20250107941A (ko) 2025-07-14
EP3288980B1 (en) 2021-03-10
KR20170140316A (ko) 2017-12-20

Similar Documents

Publication Publication Date Title
US20220281974A1 (en) Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
US20220135685A1 (en) Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
TWI821748B (zh) 使用抗pd-1抗體與抗ctla-4抗體之組合以治療肺癌
JP2022188071A (ja) 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体
CN108969763A (zh) 通过破坏pd-1/pd-l1信号传输的免疫治疗
US20230303700A1 (en) Cell localization signature and immunotherapy
JP2022512750A (ja) 黒色腫に対する併用療法
JP2022553851A (ja) 黒色腫の処置のためのｌａｇ－３アンタゴニスト
WO2018081621A1 (en) Methods of treating urothelial carcinoma using an anti-pd-1 antibody

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20180227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200317

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200814

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201110

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210309

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20210330

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210330

C27A Decision to dismiss

Free format text: JAPANESE INTERMEDIATE CODE: C2711

Effective date: 20210518

C032 Notice prior to dismissal

Free format text: JAPANESE INTERMEDIATE CODE: C032

Effective date: 20210608

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210608